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Abstract: Antiretroviral therapy (ART) has been remarkably effective in ameliorating Human Immunodeficiency Virus 
(HIV)-associated morbidity and mortality. The rapid decline in viral load during ART also presents an opportunity to 
develop a “treatment as prevention” strategy in order to reduce HIV transmission at a population level. Modelling 
exercises have demonstrated that for this strategy to be effective, early initiation of ART with high coverage of the HIV-
infected population will be required. The HIV epidemic has fueled a resurgence of tuberculosis (TB) particularly in sub-
Saharan Africa and widespread early initiation of ART could also impact this epidemic via several mechanisms. The 
proportion of patients with low CD4 cell counts who are at high risk of TB disease from progression of both latent and 
new TB infection would be greatly reduced. Entry into a life-long ART program provides an ongoing opportunity for 
intensified TB case finding among the HIV-infected population. Regular screening for HIV infection also presents an 
opportunity for intensified TB case finding in the general population. The combined effect of reduced progression of 
infection to disease and intensified case finding could reduce the overall prevalence of infectious TB, thereby further 
decreasing TB transmission. In addition, decreasing prevalence of HIV infection would reduce the TB-susceptible pool 
within the population. The ‘test and treat’ strategy therefore has potential to reduce the TB risk at both an individual and a 
population level. In this paper we explore the expected “TB dividend” of wider access to ART and also explore the 
potential of the “test and treat” strategy to impact on TB transmission, particularly in the heavily burdened setting of sub-
Saharan Africa. 
Keywords: Communicable disease control, HAART, highly active antiretroviral therapy, HIV prevention, tuberculosis 
prevention. 
INTRODUCTION 
 The strong association between Human 
Immunodeficiency Virus (HIV) and increased risk of 
tuberculosis (TB) was first described in the mid 1980s in the 
United States (US) [1, 2]. Soon thereafter, the HIV epidemic 
emerged as an important factor undermining TB control in 
both industrialized countries and resource-limited settings, 
especially sub-Saharan Africa [3]. In New York in the early 
1990s, the intersection of multi-drug resistant TB and HIV 
infection resulted in outbreaks of disease in hospitals, 
prisons and communities, and constituted a serious challenge 
to public health [4, 5]. However, rigorous implementation of 
case finding, treatment and prevention interventions in the 
city quickly brought this rising TB epidemic under control 
[5]. This was achieved using existing tools and occurred 
prior to the advent of combination antiretroviral therapy 
(ART) in the mid-1990s. 
 In contrast to the focal HIV-associated TB outbreaks and 
epidemics in the US, which have been amenable to control  
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with traditional TB control interventions, TB has proved to 
be a far greater challenge in countries with generalized HIV 
epidemics [6]. In sub-Saharan Africa, HIV has fuelled 3-5-
fold increases in TB incidence in many high HIV prevalence 
countries, especially in the south and east of the continent [6, 
7]. In the worst affected countries of South Africa and 
Swaziland, approximately 1% of the population develops TB 
each year, a majority of which is HIV-associated. The World 
Health Organization (WHO) directly observed treatment, 
short course (DOTS) strategy has failed to control this 
epidemic even in communities where this has been well 
implemented and in countries regarded as having model 
DOTS programmes [7, 8]. It has become clear that DOTS 
alone is insufficient and that multiple interventions will be 
required to address the epidemic in sub-Saharan Africa [9]. 
 ART is one of the most potent tools for preventing HIV-
associated TB [10, 11] and ART scale-up may therefore play 
an important role in controlling this epidemic. However, the 
impact of ART is likely to be highly dependent on how early 
ART is commenced during HIV progression and on the 
effective coverage that can be achieved at a population level. 
Mathematical modelling studies suggest that a strategy of 
annual HIV testing and immediate initiation of ART for all 
infected patients regardless of CD4 cell count could have a 
substantial impact on HIV transmission, thereby leading to 
reductions in HIV prevalence [12]. However, there will be 
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further benefits of this so-called “test and treat” strategy in 
reducing the TB risk at both an individual and a population 
level. In this paper we explore the expected “TB dividend” 
of wider access to ART and also explore the potential of the 
“test and treat” strategy to impact on TB transmission 
particularly in heavily burdened settings in Africa. To better 
understand this, we first discuss some of the key aspects of 
the epidemiology of TB before proceeding to describe the 
impact of ART in cohorts and communities, and we finally 
consider the potential impact of “test and treat”. 
EPIDEMIOLOGY OF HIV-ASSOCIATED TB 
 The pathway whereby HIV-infected individuals 
transition from the TB-susceptible state to TB infection, TB 
clinical disease and ultimately to TB treatment and cure is 
outlined in Fig. (1). Infection may either progress directly to 
disease (exogenous TB disease) or enter a period of clinical 
latency before reactivation at a later stage (endogenous TB 
disease). Like all other infectious diseases, the primary event 
determining the disease epidemiology is the acquisition of 
infection with Mycobacterium tuberculosis by a susceptible 
individual. 
TB Transmission Risk 
 The incidence of TB infection is very difficult to measure 
even in high TB burden settings as this requires very large 
numbers of individuals to be repeatedly tested for infection. 
Instead, it is usually preferable to measure the prevalence of 
infection according to age and then mathematically derive 
the average annual probability of infection [13]. This 
probability can be described by using two different terms - 
the current “force of infection” and the mean “annual risk of 
tuberculosis infection.” 
 The force of infection is the per capita rate at which 
susceptible (uninfected) individuals become infected each 
year and provides an assessment of the current prevailing 
infection risk in communities with a generalized TB 
epidemic. 
 In contrast, the mean annual risk of TB infection (ARTI) 
is calculated from an observed prevalence of infection at a 
given age and represents the average annual risk of infection 
since birth that would produce this prevalence. Thus, force 
of infection represents current infection risk whereas ARTI 
is an index of average infection risk over time. 
 The mean ARTI is the term most often used to describe 
risk of acquiring TB infection in childhood and has been 
used to estimate secular trends in transmission within 
populations [13]. In developed countries such as the United 
Kingdom (UK), the ARTI has continuously declined from 
over 10% in 1900, to 1% in the 1950’s and to 0.1% in the 
1990’s [14]. However, the ARTI in developing country 
settings has remained high. In a study of southern African 
school children, the ARTI was estimated to be between 0.8% 
and 2.5% in Zambia and between 2.5% and 4.2% in South 
Africa [15, 16]. In Cape Town, South Africa, the high rate of 
acquisition of TB infection in African township residents 
was shown to continue throughout childhood into young 
adulthood and the force of TB infection was estimated to be 
6.8%-7.9% for those between 15 and 20 years of age [17]. A 
high force of infection results in exogenous primary and 
secondary TB infections, which will rapidly progress to 
clinical disease, particularly in HIV-infected individuals with 
low CD4 cell counts [18]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A model for HIV-associated tuberculosis (TB) epidemiology following the pathogenesis of TB from infection, to endogenous or 
exogenous disease, to treatment and cure. The transition from infection to disease is shown to be CD4 cell dependent. The transition from 
disease to TB treatment is affected by case finding. The force of TB infection is determined by prevalence of TB disease and the effective 
contact number. The progression from treatment to cure is primarily affected by the functioning of the directly observed treatment, short 
course (DOTS) programme. 
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 Fig. (2) illustrates the impact of high ARTI and high 
force of TB infection on patients presenting to an ART clinic 
in scenarios of low, medium and high TB transmission. 
Latent infection would be present in approximately 1.3%, 
12.4% and 74% in settings where ARTI is 0.04%, 0.4%, or 
4% per annum, respectively. Active TB disease in the low 
and medium transmission settings would be predominantly 
due to reactivation from latent infection, although limited 
explosive outbreaks may still occur when the local force of 
infection is high due to uneven distribution within the 
population [19]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Illustrative values for typical proportions of tuberculosis 
(TB) infection and disease of HIV-infected patients entering 
antiretroviral therapy (ART) care in scenarios with low, medium 
and high TB force of infection. Values of infected proportions are 
calculated for a cohort with mean age 33 years resident in 
communities with mean annual risk of TB infection (ARTI) of 
0.04%, 0.4% and 4%. (TB disease data from: Lawn SD, Fraenzel 
A, Kranzer K, et al. [35]). 
 In contrast, in high transmission settings, the large 
proportion of individuals with latent infection and the 
prevailing high force of infection would lead to both 
increased reactivation and increased primary and secondary 
TB re-infection disease. Therefore, interventions which 
modify progression from latent TB infection to active TB 
disease, such as short-term TB preventive treatment with 
isoniazid, would be expected to be effective where TB 
disease was predominantly due reactivation but less so where 
force of infection is high [20]. In contrast, the relative benefit 
of ART would be similar in either high or low transmission 
settings [20]. 
Prevalence of Untreated TB 
 The force of infection is determined by the prevalence of 
infectious TB (untreated or inadequately treated) in a 
community and the number of secondary cases resulting 
from each infectious case (effective contact number). 
However, the prevalence of TB is also a parameter which is 
difficult to measure directly and therefore is frequently 
estimated from other TB parameters such as case notification 
rates and TB mortality rates [7]. Some data, however, are 
available. For example, in 2005 prior to widespread access to 
ART, the prevalence of untreated TB among a population 
sample of randomly selected individuals in a Cape Town 
community was 1.6%, with prevalence rates of 5.2% and 
0.5% in the HIV-infected and HIV-uninfected populations, 
respectively [21]. 
 In scenarios where most TB cases eventually enter the 
TB control program and in a stable epidemic situation, the 
mean duration of infectiousness before starting effective 
chemotherapy can be approximated by the untreated TB 
prevalence divided by the TB incidence rate. Aggressive 
scale-up of HIV testing and provision of longitudinal HIV 
care in communities would provide the opportunity for 
greatly improved TB case finding, thereby reducing the 
prevalence of untreated TB. This, in turn, would be 
associated with shortening of the disease duration and 
reduced TB transmission risk. Thus, to better understand the 
potential impact of ART on TB transmission within 
communities, it will be important to assess the impact of 
ART scale-up on TB prevalence and disease duration. 
Effective Contact Number 
 The impact of social factors on TB transmission and 
disease has been long recognised. Social crowding in poorly 
ventilated housing resulted in exceptionally high TB rates in 
urbanised populations of the nineteenth century [22]. An 
effective TB contact is defined as a contact between an 
infectious pulmonary case and a susceptible individual 
sufficient to result in TB infection [23]. In the UK, the 
effective contact number has been estimated to have declined 
from approximately 22 in 1900 to 10 in 1950 and between 1 
and 2 by 1990 [14]. It is assumed that the reduction in 
effective contact number was a result of steady improvement 
in social circumstances including decreased household 
crowding [14]. 
 In Cape Town, the effective contact number is between 
11and 22 cases infected for each smear-positive notified case 
[24]. The effective contact number has epidemiologic 
importance because if it is less than the reciprocal of the life-
time risk of TB disease, the TB epidemic will decline. Thus, 
for example, when the population life-time risk of 
developing pulmonary TB is 10%, an effective contact 
number of less than 10 would be sufficient to result in 
decline in TB transmission. However, in South Africa with 
over 5.5 million HIV-infected individuals [25] who have an 
approximate 10% risk of developing TB each year, both the 
effective contact number and the prevalence of infectious TB 
need to be greatly reduced to bring the TB epidemic under 
control. 
EXISTING TB CONTROL INTERVENTIONS 
 Combination anti-tuberculosis treatment rapidly 
decreases the infectiousness of drug-sensitive TB cases [26]. 
Treatment therefore can effectively decrease ongoing 
transmission from individuals who are identified by the TB 
control program and expeditiously started on effective 
chemotherapy. Thus, the principal TB control intervention of 
the WHO is the directly observed treatment, short course 
(DOTS) treatment strategy, and implementation of this has 
been associated with ongoing improvements in TB control in 
many settings [7]. 
100
io
n
ARTI = 0.04% pa
ARTI = 0.4% pa
60
80
te
d 
po
pu
la
ti ARTI = 4% pa
40
of
 H
IV
-in
fe
ct
20
Pr
op
or
tio
n 
o
0
Susceptible TB infected TB disease
P
386    Current HIV Research, 2011, Vol. 9, No. 6 Wood and Lawn 
 The focus of DOTS is on effective case management of 
self-referred symptomatic patients (passive case finding) and 
thus removing them from the infective pool. The rates of TB 
disease are now so low in many industrialised countries that 
alternative active case finding strategies are no longer 
considered cost-effective [27]. It has been noted that the 
annual risk of infection and effective contact number 
declined markedly in industrialized countries during the first 
half of the twentieth century even prior to the availability of 
effective chemotherapy [14]. Thus, the DOTS strategy may 
have consolidated TB control rather than initiated it. 
 However, in countries with generalized TB and HIV 
epidemics, the DOTS strategy has failed to reverse the 
increasing TB burden. In highly burdened countries, many 
individuals with HIV-associated TB progress to death 
without their TB disease being recognised [28-31]. Where 
HIV is endemic, the effective contact number and rates of 
progression to active TB are high such that the DOTS 
strategy may have insufficient impact on the prevalence of 
HIV-associated TB to reduce ongoing TB transmission. The 
combination of a high prevalence of unrecognised infectious 
TB and high effective contact number combine to maintain a 
high force of infection, which is further amplified by a large 
number of susceptible HIV-infected individuals, many of 
whom have advanced immune suppression. 
ANTIRETROVIRALS AND TB RISK 
 Having described how DOTS is insufficient to address 
the challenge presented by the HIV-associated TB epidemic 
in Africa, we now consider the potential role of ART, 
drawing together data on the burden of TB occurring prior to 
ART, changing TB risk during in cohorts receiving ART and 
the modelled and observed impact of ART at a population 
level. 
Tuberculosis in Patients Initiating ART 
 South Africa is a country where both HIV and TB are 
endemic [32]. TB and HIV care services have developed 
separately although there have been increasing efforts to 
integrate these programs [33, 34]. The diagnosis of HIV in 
attendees of TB services has always been a major pathway 
for access to HIV care and ART provision in South Africa. 
In a large Cape Town community ART clinic, approximately 
16% of referrals between 2002 and 2005 were from the 
national TB control program [35]. However, following the 
introduction of provider-initiated HIV testing and 
counselling within the TB service in 2005, there was a 
steady increase in the proportion of direct referrals from the 
TB service to account for 35% of patients in 2007-2008 [35]. 
The proportion of these patients whose disease was a 
recurrent TB episode also decreased from 8.6% to 3.2% over 
the same time period, which is consistent with another report 
that TB recurrences were approximately halved by ART in 
Rio de Janeiro [36]. 
 In addition to those HIV-infected patients referred to the 
ART clinic with a known TB diagnosis, many of the 
remaining patients accessing the ART service from other 
referral sources also had TB diagnosed during intensive pre-
ART screening (approximately 25%) [37, 38]. Therefore, the 
total burden of TB disease in those starting ART at this 
clinic was extremely high. Thus, in the current situation in 
which patients typically access ART with advanced 
symptomatic disease, over half the patients at this service 
have TB at the time of ART initiation, thereby severely 
limiting the potential of ART as a TB preventive 
intervention [39]. 
Individual Level Impact of ART on TB Risk and TB 
Mortality 
 Initiation of ART leads to rapid functional recovery of 
mycobacterium-specific immune responses, with increasing 
lymphocyte proliferation of cells which are able to secrete 
interferon-gamma when stimulated ex vivo with 
mycobacterial antigens [40-43]. Such immunologic 
responses have been shown to be associated with an 
enhanced capacity to restrict in vivo mycobacterial growth 
[44]. ART has therefore a potent capacity to improve an 
individual’s ability to control TB infection and decrease the 
rate of progression to clinical disease following recent or 
latent TB infection [44]. 
 In the high burden setting of South Africa (Fig. 3), use of 
ART was associated with a TB risk reduction of 
approximately 80% in patients followed up for 15 months 
[10]. The reduced TB risk was seen across a broad range of 
baseline CD4 cell counts and WHO stages of disease [10]. 
Those patients with advanced clinical stage and with lowest 
CD4 cell counts had the greatest number of TB cases 
averted. However, the TB incidence rates remained high 
over this relatively short period of follow-up at 3.4/100 
person-years and 4.6/100 person-years for those with 
baseline CD4 cell counts <200 cells/mm
3
 and WHO stage 3 
or 4 disease, respectively [10]. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Tuberculosis (TB) incidence (cases per 100 patient years) 
for HIV-infected patients attending outpatient services in Cape 
Town, South Africa. Patients were stratified by CD4 cell count and 
World Health Organization clinical stage. Use of antiretroviral 
therapy was associated with an approximate 80% reduction of TB 
incidence over a mean follow-up period of 15 months. (Data from 
Badri M, Wilson D, Wood R. [10]). 
 Data from multiple other cohort studies in both high-
income and resource-limited settings report [10, 45-52] 
reductions in TB incidence of 54-92% in adjusted analyses 
(Fig. 4A). A summary analysis of these results [53] 
estimated an overall risk reduction of 67% (95% confidence 
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intervals [CI] 61-73). Of note, reductions in TB incidence 
are similar in patients with either positive or negative 
tuberculin skin tests [54], suggesting that ART impacts the 
risk of progression to TB disease following either 
endogenous reactivation or exogenous exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). A. Adjusted hazard ratios comparing tuberculosis (TB) 
incidence in HIV-infected individuals receiving antiretroviral 
therapy (ART) compared with those not receiving ART. Data from 
nine cohort studies in 5 countries [10, 40-47]. B. Adjusted hazard 
ratios comparing tuberculosis (TB) case fatality rates for HIV-
infected individuals receiving antiretroviral therapy (ART) 
compared with those not receiving ART. Data from seven cohort 
studies in 5 countries [55-61]. 
 TB incidence rates continue to decline during ongoing 
ART, as a result of ongoing immune recovery [55-57]. The 
current CD4 cell count at any given time during ART 
appears to be the primary determinant of current TB relative 
incidence risk [55]. A 10-fold reduction in relative TB risk is 
observed as CD4 cell counts increase from <100 cells/ mm
3
 
to >500 cells/ mm
3
 (Fig. 5). It is still unclear whether 
incident TB during ART is due to predominantly reactivation 
or re-infection. However, it has been suggested that in the 
context of a rising CD4 cell count during ART, reinfection is 
likely to be the predominant mechanism, whereas both are 
likely to be important in patients with falling CD4 cell 
counts [20]. 
 In the Cape Town treatment cohort, the highest TB rates 
are seen when significant person-time was spent at low CD4 
cell counts (<200 cells/ mm
3
); an intermediate risk when 
CD4 cell counts were in the intermediate range of 200-500 
cells/ mm
3
 and the lowest incidence rates when the current 
CD4 cell counts exceeded 500 cells/ mm
3
 (Fig. 5) [57]. 
However, even among these patients with the highest CD4 
cell counts, absolute TB rates were still approximately two-
fold higher than rates among HIV-uninfected people living 
in the same community [57, 58]. 
 Case fatality rates are several-fold higher among HIV-
infected TB patients than among those without HIV  
 
infection, and mortality is related to the degree of 
immunodeficiency [59, 60]. Analyses of observational 
cohort data adjusted for baseline patient characteristics (Fig. 
4B) demonstrate that the mortality risk reduction associated 
with current ART was between 64-95% [61-67]. Further 
benefits include improved TB treatment outcomes, with 
some data suggesting an increased rate of sputum smear 
clearance [61] and a decreased risk of recurrent TB [36]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Changes in CD4 cell counts during 4 years of antiretroviral 
therapy. The graph shows the changes in proportions (%) of 
patients with CD4 cell counts below the threshold of 1000 cells/ 
mm
3
 stratified into 100 CD4 cell strata. The tuberculosis (TB) 
incidence risk ratios (IRR) are shown for each stratum with the 
comparator being the CD4 cell stratum greater than 500 cell/ mm
3
. 
The IRR are greatest in the lower CD4 cell strata. The proportions 
of patients with less than 300 cells/ mm
3
 decreased over 4 years. 
(Data from Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. 
[57]). 
 Current international guidelines recommend ART for all 
TB co-infected patients regardless of CD4 cell count and it is 
to be hoped will lead to reductions in TB case fatality rates 
[68]. However, unfortunately many cases of TB in HIV-
infected individuals remain undiagnosed during life and TB 
remains a significant cause of pre-ART mortality [28-31, 69, 
70]. Thus, while the current ART treatment paradigm 
decreases incident TB and TB case fatality while on ART, 
the majority of patients present after developing TB disease 
and so there is little impact on population TB transmission 
and incidence. 
Modelling Studies of Population Impact of ART on TB 
 The impact of ART on TB incidence rates in any given 
population will depend on its impact on the probabilities of 
transition from TB susceptibility to TB disease and eventual 
cure, remission or death (Fig. 1). In industrialized countries, 
TB is a rare disease characterised by stochastically-driven 
small outbreaks rather than by a generalised transmission 
within the population as a whole [19]. As TB burden has 
decreased continuously over the last century, the force of 
infection, latent pool of infection and prevalence of untreated 
disease are so low that direct measurement would be 
impracticable. 
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 However, in settings with high TB burdens, knowledge 
of the size of the different TB-affected populations and 
impact of ART on the transition probabilities between states 
is important to predict effectiveness of “test and treat” as a 
public health intervention. Unfortunately there has been little 
effort to address the basic epidemiology as there has until 
recently been a reliance on the DOTS strategy alone. In most 
heavily burdened settings, the force of infection, latent 
infected pool, proportion of disease due to recent infection, 
effective contact number and prevalence of drug-sensitive 
and drug-resistant infectious TB disease are largely 
unknown. 
 HIV-TB epidemic models have been either computer 
simulations or simple mathematical studies focusing on 
steady states and their stability. These models generally 
contain many unknown parameters and rely on few data 
[71]. Modelling exercises utilising the known individual 
benefits of ART have been used to try to estimate the 
population impact of ART. A model incorporating HIV 
cohort data that included the known rate of CD4 cell decline, 
the incidence of TB as a function of CD4 cell count, HIV 
survival and the short-term efficacy of ART in TB 
prevention identified that early, high ART coverage 
combined with good compliance would be necessary to 
substantially impact on TB incidence [72]. It was concluded 
that the present ART strategies would support curative 
treatment rather than serve as an effective TB preventive 
intervention. However, this model did not include impact of 
ART on either TB transmission or HIV transmission. 
 Another simple compartmental mathematical model was 
able to reproduce the historical longitudinal HIV-TB 
incidence for a single high burdened South African 
community and indicated that ART could further reduce TB 
notification rates [71]. This model incorporated the “Styblo 
Ratio” of a fixed relationship of 10-14 new infections per 
annum for each untreated TB case as a measure of the 
effective contact number. 
 Recent mathematical modelling studies have explored the 
effect of widespread implementation of ART instituted soon 
after acquisition of HIV infection on the HIV epidemic [12], 
and these analyses have now been extended to consider the 
additional impact on the HIV-associated TB epidemic [73]. 
A model was fitted to the South African HIV epidemic curve 
and TB notification rates indicated that use of ART as soon 
as individuals test HIV-positive (the “test and treat” strategy) 
could rapidly reduce pre-ART TB cases and more slowly 
impact on-ART incident TB cases. This model incorporated 
the impact of ART on HIV transmission, with which control 
of the HIV-associated TB epidemic could be achieved after 4 
decades. However, the model assumed no TB transmission 
interactions between HIV-positive and HIV-negative 
individuals. Both HIV-positive and HIV-negative adult 
smear-positive TB index cases have been geographically 
linked with household acquisition of childhood TB 
infections [74]. Therefore, reduction in HIV-associated 
smear-positive disease would be expected to result in some 
reduction of transmission. 
 In summary, modelling exercises suggest a probable 
impact of ART on TB incidence predominantly impacting 
HIV-infected individuals, with the magnitude of impact 
dependent on coverage achieved and the time interval 
between HIV seroconversion and start of ART. 
Observed Population Impact of ART on TB 
 In contrast to the numerous studies of TB incidence in 
ART-treated cohorts, there are few data recording the impact 
of ART on TB incidence or prevalence at a population level. 
A retrospective analysis of surveillance data from AIDS 
patients in Rio de Janeiro during the first 3 years of ART 
provision demonstrated a decline in incidence of TB 
diagnosed within one year from an AIDS diagnosis from 
24.4% to 15.2% [75]. However, another study from Rio de 
Janeiro covering the same period reported that TB was the 
primary cause of AIDS deaths, which were often 
misclassified, and their analysis could not demonstrate any 
benefit of ART on TB [76]. 
 A prospective observational study was performed in a 
high HIV and TB burden community of approximately 
15,000 persons in South Africa between 2002 and 2008, 
when access to ART rapidly increased from 0% to 25% of 
the HIV-infected population [8, 21, 77]. Adult TB 
notifications increased to a maximum of 2500 cases per 
100,000 population between 2002 and 2005, and decreased 
thereafter to 2000 cases per 100,000 population in 2008 [77]. 
 In observational data, an association between decreasing 
TB incidence with increasing ART usage does not 
necessarily prove causality. However, the magnitude of the 
decrease in TB incidence paralleled the increasing ART use. 
Moreover, in sub-analyses the decline in TB incidence rate 
was only observed in the HIV-infected population receiving 
ART and remained stable in both the other sub-populations 
of individuals who were either HIV-positive and not 
receiving ART or who were HIV-negative [77]. The decline 
in TB incidence is much more likely to have resulted from 
an improving temporal trend in the CD4 cell count profile 
rather than from any deterioration in ascertainment of TB 
among those within the ART program. 
 The results of two cross-sectional TB prevalence surveys 
performed in the same South African community in 2005 
and 2008 at different stages of ART scale-up are shown in 
Fig. (6) [21, 77]. The TB prevalence among a randomly 
selected HIV-positive population sample was 9.2 % in 2005 
and 3.6% in 2008, while the corresponding ART coverage 
rates in the community were 13% and 21%. The most 
marked change between the surveys was a significant 
(p<0.01) four-fold decrease in laboratory confirmed 
untreated prevalent cases of HIV-associated TB. This 
reduction could result either from a decrease in the 
proportion of individuals with profound immune suppression 
in the community or from increased TB case finding 
associated with the implementation of the ART program. It 
is not possible to distinguish the relative contribution of 
these two mechanisms. 
THE EFFECTS OF “TEST AND TREAT” ON TB 
CONTROL 
 There has been a call to test the efficacy of the “test and 
treat” strategy in controlled environments [78]. While scale-
up of “test and treat” is intended to target HIV incidence  and  
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Fig. (6). The prevalence of untreated and treated tuberculosis (TB) 
in random population samples of HIV-infected residents in 2005 
and 2008 of a South African township. Untreated TB was 
confirmed by Mycobacterium tuberculosis culture. There was a 
significant decrease in prevalent TB between the two surveys with 
the greatest decline in previously unrecognised TB. (Data from 
Wood R, Middelkoop K, Myer L, et al. [21] and Middelkoop K, 
Bekker L-G, Myer L, et al. [77]). 
long-term HIV prevalence, additional potential impacts on 
TB epidemic parameters are outlined in Table 1. These 
represent the parameters with which the impact of 
implementation of the “test and treat” strategy might be 
measured. Such evaluation would require prospective 
surveillance and detailed and comprehensive surveys within 
implementing communities. 
 The primary effects of early and widespread introduction 
of ART on TB would be by increasing the overall 
distribution of CD4 cell counts in the HIV-infected 
population pool. TB risk approximately doubles soon after 
HIV seroconversion [58] and patients receiving ART and 
who have CD4 cell counts >500 cells/ mm
3
 have a 
comparable risk to this [55]. Thus, patients who initiate ART 
early in the course of HIV infection are likely to remain at 
approximately just twice the risk of incident TB compared 
with HIV-negative peers. In contrast, for those who have 
already progressed to low CD4 cell counts by the time of 
HIV diagnosis and ART initiation, the time course 
demonstrated in Fig. (5) suggests that it would require 
greater than 5 years to achieve substantial decreases in the 
relative risk of incident TB. 
 Patients receiving ART have greatly improved survival 
and will remain at increased risk of incident TB. Net 
reduction in HIV-associated TB rates will be achieved by 
reduction of time spent at low CD4 cell counts and further 
impacted by long-term reductions in HIV prevalence. 
Occurrence of HIV-associated TB at higher CD4 cell counts 
overall will be associated with lower mortality risk. 
Table 1. The Potential Additional Impact on the HIV-Associated TB Epidemic of Implementing the ‘Test and Treat’ Strategy of 
ART Scale-Up Compared to Scale-Up of ART According to Conventional National Plans 
 
 Impact of ‘Test and Treat’ ART Scale-Up 
Population CD4 cell count distribution Increase in median and overall distribution of CD4 cell counts among HIV-infected patients, favourably 
impacting overall population CD4 cell count distribution 
HIV-1 incidence Reduced by decreasing HIV-1 transmission risk 
HIV-1 prevalence Short-term reductions in prevalence partially offset by increased survival, but substantial long-term reductions  
TB case finding Greatly increased among HIV-infected population during pre-ART screening and ‘unmasking’ of TB during 
early ART and increased surveillance during ART. Also potential for TB screening to be linked to HIV testing 
among general population 
TB incidence rates in patients receiving 
ART 
Lower due to less cumulative time accrued at low CD4 cell counts 
Proportion of HIV-associated TB 
occurring pre-ART 
Greatly reduced with ART initiation at high CD4 cell counts 
Proportion of HIV-associated TB 
occurring during ART 
Increased as person-time living with HIV-1 infection accrued prior to ART is greatly reduced. 
Total HIV-associated TB rates in the 
population 
Net reduction in HIV-associated TB rates, due to overall reduction in person-time accrued at lower CD4 cell 
counts and long-term reductions in HIV prevalence 
CD4 cell counts among incident HIV-
associated TB cases 
Much higher median and distribution. 
TB prevalence and TB disease duration Likely to be reduced in HIV-infected population due to improved CD4 count distribution and due to TB 
screening leading to improved case finding among patients in care 
TB transmission Reduced TB prevalence and disease duration in HIV-infected patients may reduce TB transmission risk 
HIV-associated TB mortality Greatly reduced due to increased case ascertainment and treatment and occurrence of TB at higher CD4 cell 
counts  
TB, tuberculosis; ART, antiretroviral therapy. 
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 The combination of reduced progression from TB 
infection to TB disease among HIV-infected patients, 
improved TB case finding among those on ART and 
incorporation of regular TB symptom screening in the HIV-
uninfected population could reduce TB force of infection. 
Thus, widespread implementation of “test and treat” could 
use “treatment as prevention” to assist in the control of both 
the HIV and TB epidemics. 
SUMMARY 
 There is considerable evidence from observational 
cohorts that ART improves survival and decreases the rate of 
progression from both recent and latent TB infection to 
clinical disease. The population impact of ART is less clear, 
as increased survival of individuals with low CD4 cell 
counts could increase the proportion of a population at 
increased risk of progression to TB disease. In the absence of 
empiric data, modelling studies have indicated that earlier 
initiation of ART on a wide scale could significantly impact 
on TB rates in heavily burdened countries. There is now 
some early observational data from population studies 
confirming that TB prevalence and incidence may be 
reduced by ART. 
 The population impact of ART on HIV-TB rates may 
occur by three predominant means. First, ART can improve 
the CD4 cell count profile of a population and therefore 
decrease progression from infection to TB disease. Second, 
HIV-infected individuals on ART receive longitudinal care, 
providing the opportunity for improved TB case detection 
and decrease in the prevalence of untreated TB. Third, 
widespread early implementation of ART may reduce the 
HIV incidence rate and eventually the prevalence of HIV 
infection. 
 Modelling studies have not explored the TB transmission 
between the HIV-infected and -uninfected population pools 
as it has been thought that few HIV negatives acquire TB 
infection from patients with HIV-associated TB. This 
interaction may have been underestimated because of the 
long inter-generation time between transmission of infection 
from HIV-associated TB cases and subsequent development 
of TB cases in HIV-negative individuals. Further long-term 
molecular epidemiologic studies will be required to clarify 
this interaction. Long-term benefits of HIV-TB control for 
HIV negatives would be an additional impetus for the “test 
and treat” strategy. 
 HIV has been considered the primary driver of the 
explosion of HIV-associated TB epidemic in southern 
Africa, but it may also be considered to be fuel poured on an 
existing fire. HIV infection has amplified the high force of 
TB infection still existing in many parts of the developing 
world. Control of HIV-associated TB is therefore not 
isolated from general population TB control. A “test and 
treat” strategy may provide an additional opportunity for 
improved general population screening for TB in high 
burdened settings. 
ABBREVIATIONS 
ART = Antiretroviral Therapy 
ARTI = Annual Risk of Tuberculosis Infection 
DOTS = Directly Observed Treatment, Short Course 
HAART = Highly Active Antiretroviral Therapy 
HIV = Human Immunodeficiency Virus 
SACEMA = South African Centre for Epidemiological  
   Modelling and Analysis 
TB = Tuberculosis 
UK = United Kingdom 
US(A) = United States (of America) 
WHO = World Health Organization 
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